- Home
- AIHS vs NRXS Comparison
AIHS vs NRXS Comparison
Compare AIHS & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIHS
- NRXS
- Stock Information
- Founded
- AIHS 2014
- NRXS 2011
- Country
- AIHS China
- NRXS United States
- Employees
- AIHS N/A
- NRXS N/A
- Industry
- AIHS Finance: Consumer Services
- NRXS
- Sector
- AIHS Finance
- NRXS
- Exchange
- AIHS Nasdaq
- NRXS Nasdaq
- Market Cap
- AIHS 11.9M
- NRXS 13.0M
- IPO Year
- AIHS 2018
- NRXS 2023
- Fundamental
- Price
- AIHS $0.32
- NRXS $2.49
- Analyst Decision
- AIHS
- NRXS Strong Buy
- Analyst Count
- AIHS 0
- NRXS 1
- Target Price
- AIHS N/A
- NRXS $7.00
- AVG Volume (30 Days)
- AIHS 4.2M
- NRXS 155.9K
- Earning Date
- AIHS 08-13-2025
- NRXS 08-08-2025
- Dividend Yield
- AIHS N/A
- NRXS N/A
- EPS Growth
- AIHS N/A
- NRXS N/A
- EPS
- AIHS N/A
- NRXS N/A
- Revenue
- AIHS $5,878,700.00
- NRXS $2,934,945.00
- Revenue This Year
- AIHS N/A
- NRXS $138,883.78
- Revenue Next Year
- AIHS N/A
- NRXS $118.59
- P/E Ratio
- AIHS N/A
- NRXS N/A
- Revenue Growth
- AIHS 12.21
- NRXS 27.52
- 52 Week Low
- AIHS $0.26
- NRXS $1.33
- 52 Week High
- AIHS $1.70
- NRXS $6.20
- Technical
- Relative Strength Index (RSI)
- AIHS 30.64
- NRXS 49.91
- Support Level
- AIHS $0.29
- NRXS $2.33
- Resistance Level
- AIHS $0.35
- NRXS $2.67
- Average True Range (ATR)
- AIHS 0.16
- NRXS 0.17
- MACD
- AIHS -0.06
- NRXS -0.01
- Stochastic Oscillator
- AIHS 3.70
- NRXS 46.43
About AIHS Senmiao Technology Limited
Senmiao Technology Ltd is a holding company. The company's operating segment includes Automobile Transaction and Related Services focusing on the online ride-hailing industry in the People's Republic of China and Online ride-hailing platform Services through its own platform, Xixingtianxia. It generates maximum revenue from the Automobile Transaction and Related Services segment. Geographically, it derives revenue from China.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).